Brief Article
Copyright ©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 14, 2010; 16(46): 5881-5888
Published online Dec 14, 2010. doi: 10.3748/wjg.v16.i46.5881
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Immunohistochemistry showing phosphatase and tensin protein expression. A: Patients with absent phosphatase and tensin (PTEN) expression (HE stain, × 400); B: Patients showing positive PTEN expression (HE stain, × 400).
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Progression-free survival time of patients with or without KRAS mutation (A) and phosphatase and tensin protein expression (B). A: P < 0.001; B: P = 0.07. PFS: Progression-free survival.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Overall survival time of patients with or without KRAS mutation (A) and phosphatase and tensin protein expression and skin toxicity (B). A: P < 0.001; B: P = 0.004. OS: Overall survival.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Overall survival and progression-free survival time of patients with or without favorable prognostic factors. A: P < 0.001; B: P = 0.001. 0: KRAS mutation and loss of phosphatase and tensin (PTEN); 1: Either no KRAS mutation or normal PTEN expression; 2: No KRAS mutation and normal PTEN expression. OS: Overall survival; PFS: Progression-free survival.